Connecting and advancing health sciences in partnership with academic and clinical institutions

from Open access to Artificial Intelligence Discovery tools - Karger Publishers offers services that make the world of research go round
Overview

1. Introduction
2. The Karger Approach
3. Qinsight – AI Discovery tool
4. Karger - Open for Open
5. Q & A
1. Introduction

A Family Business

- Founded by Samuel Karger in 1890
- Managed by the 4th generation of the Karger family
- Headquarters at Basel (Switzerland)
- International organization: Regional offices on 5 continents and collaboration with representatives in the whole world
1. Introduction

Facts and Figures

- 104 journal titles (28 Open Access)
- Fast Facts medical handbooks : 33 new books in 2019
- 15 new book titles per year
- Publication language: English (97%)
- 8'100 published articles
- 170 Editors-in-Chief & 3’250 Editorial Board Members worldwide
- approx. 12’800 Peer Reviewers worldwide
- Development of new tools, services and apps
1. Introduction

A long history...

Many Karger titles have a long history, published for many decades – well-established journals of high reputation that in their area serve as a forum for the latest developments and findings of basic and clinical research:

**Dermatology** (1893)

**Psychopathology** (1897)

**Cardiology** (1937)

**Advances in Cardiology** (1939)
2019 – a new strategy

• A new mission statement: Connecting and advancing health sciences Knowledge that matters. Experiences that make a difference.

• Karger established 2 main divisions:
  • “Academic and Research Markets” (ARM) – with services for academic institutions, societies and research companies.
  • “Karger Clinical & Healthcare Clients” - providing scientific findings edited for clinicians and patients.

• Libraries and publishers have always shared a core mission → to help knowledge reach the people who need it.

• Open Access is re-defining the roles of libraries/institutions and publishers.

• Therefore, our focus is shifting to filtering, generating and publishing content – content that matters.

• This means that the entire cycle of knowledge is coming into the picture…
2. The Karger Approach.

The Cycle of Knowledge

Our mission is to connect and advance health sciences.

We have developed new services and partnerships, that cover diverse needs along the research cycle:

**Publish**
In partnership with institutes, our solutions make it easy for faculty members to publish Open Access with a reputed publisher.
- Publish & Access with APC vouchers, combining access to the complete Karger collection and publishing options in all Karger journals
- Start your own Open Access Partner Publication with Karger: now offering a step by step program for institutions and societies.

**Access**
Complete collection, customized collection, subject package, individual journal subscription or topic article package: let us provide you with an access model that fits your needs!

**Curate**
Searching through a flood of content, trying to find and compile the relevant information can be extremely time consuming. We are proud to support you and your faculty in the task of curation and simplify the research process with the AI-based discovery solution Qinsight.

**Services**
In cooperation with Enago, as of fall 2019 Karger will offer a wide range of educational workshops and trainings for a broad variety of audiences, from young authors just starting their careers to reviewers and editors. All workshops can be held online or in person, depending on your preferred method and setting. Additional services covering more needs will follow in the future.
Fast Facts Medical handbooks for clinicians & for patients

Dermakonsil – an app for dermatologists

Karger LEARN platform and educational services

Struggling with writing and publishing your research?
We can guide you through the publication process and help you achieve success.
Register Now
3. Qinsight: Searching Biomedical Literature with AI
What is Qinsight?

- An AI-based platform, enabling efficient discovery of relevant results
- It is specialized in Biomedical literature
- Qinsight allows you to search in natural language
- Qinsight finds meaningful relationships between concepts and predictions not possible with other systems
- Covering >40 million documents, including >10M full-text
3. Qinsight – discover, explore, analyse

Access to which Content?

- Journal articles – All biomedical articles including all of PubMed/MEDLINE, plus full-text non-open access articles from publisher partners (ex: Karger, OUP)
- Clinical Trials – covering all content from clinicaltrials.gov
- NIH Grants – providing insight into what is being worked on even before journal publication
- Patent Grants – covering full-text for all granted US patents
- Patent Applications – covering full-text for all US patent applications
- AHRQ Treatment Guidelines – covering clinical practice guidelines from the National Guidelines Clearinghouse
- Toxline – including both NTIS documents and Riskline
- HSTalks – online seminars by leading world experts, covering biomedicine and life sciences
- Health and Life Science News – providing access to breaking information without waiting for full publication. If you have a subscription to Factiva from Dow Jones, that deep news source can also be integrated into your Qinsight subscription.
Focused Results (437)

1. Regulation of IL-8 gene expression in gliomas by microRNA miR-93.
   Fabbri E (Department of Life Sciences and Biotechnology Section of Biochemistry and Molecular Biology University of Ferrara Via Fossato di Mortara)
   BMC Cancer (2015) Show Abstract
   IL-8 is a putative target of miR-93 in gliomas

   Ahn SH (Department of Neurosurgery, Korea University College of Medicine, Seoul, Korea)
   IL-8 promotes tumoral angiogenesis and increases brain endothelial cell permeability in glioblastoma.

3. Critical Role of IL-8 Targeting in Gliomas.
   Kosmopoulos M (Department of Biological Chemistry Medical School National and Kapodistrian University of Athens 11527 Athens, Greece)
Interleukin-8 (IL-8) has been revealed as a critical regulator of CNS function and development with participation in many CNS disorders including gliomas.

More Relevant Statements

Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.

Hasan T (Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA)

More Authors

Cell Death Dis (2019) Show Abstract

In sum, our data show that IL-8 is a key microenvironmental factor involved in promoting cellular plasticity in GBM.

More Relevant Statements

The Process and Regulatory Components of Inflammation in Brain Oncogenesis.

Mostafa AG (Department of Biomedical Sciences and Cancer Biology, Center School of Pharmacy, Texas Tech University Health Sciences Center

More Authors

Biomolecules (2017) Show Abstract

High-grade gliomas show increased expression of IL-8.

More Relevant Statements

Cytokine patterns in brain tumour progression.

Albulescu R (Victor Babes National Institute of Pathology, 99-101, Splaiul Independentei 050111, Bucharest, Romania)

More Authors

Mediators Inflamm (2013) Show Abstract

Many studies showed that IL-8 is upregulated in gliomas and is involved in the promotion of angiogenesis.

More Relevant Statements

Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment.

Chulpanova DS (OpenLab Gene and Cell Technologies Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia)

More Authors

Front Pharmacol (2018) Show Abstract

IL-8 dependent recruitment of MSCs was also detected in glioma.

More Relevant Statements

The prolyl isomerase Pin1 regulates the NF-kappaB signaling pathway and interleukin-8 expression in glioblastoma.

Atkinson GP (Department of Cell Biology, University of Alabama at Birmingham, Birmingham, AL, 35294-0006, USA)

More Authors

Oncogene (2018) Show Abstract

IL-8 is particularly important in tumor angiogenesis, and studied extensively with respect to human gliomas.

More Relevant Statements

IL-8 is a mediator of NF-kB induced invasion by gliomas.

Ravichandran B (Brain Tumor and Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue, NIP 46, Cleveland, OH 44195, USA)

More Authors

More Relevant Statements
Predictive Visual Analytics

• Visual analytics help us to understand and explore information.

• The **Concept Cloud** visualizes the answers to questions like:
  - How do concepts relate to each other?
  - Are there any emerging trends?
  - What other concepts should I pay attention to?

The **red** fringe indicates a growing trend in research, a **blue** fringe indicates a waning trend, grey no significant momentum change.
Visual Analytics

Qinsight will also provide you with information on **Connections**

Not just their simple co-occurrence in a document, but visualizing the **strength and significance** of the connections.

The deeper the orange color, the stronger the connection.

Find and highlight the most relevant results – with Qinsight.
5 Reasons why...

... Qinsight would help you:

1. Qinsight enables efficient discovery of relevant results.
2. Qinsight saves time by producing relevant results quickly, instead of overwhelming lists.
3. Qinsight finds meaningful relationships between concepts and predictions not possible with other systems.
4. Qinsight helps in many different contexts: early phase research (ex: predictive analysis), as a valuable complement to traditional Systematic Review approach, etc.
5. Qinsight is easy to use!
Qinsight – our proposal

- Invite you to look at a recorded webinar (28mn) made by Jeff Saffer, one of the founder of Qinsight, explaining and showing how Qinsight works.
- The topic chosen to illustrate this is “metformin and diseases”.
- We offer academic and hospital institutions a free trial of a month.
- During the trial you would receive documentation and Tips on how to best use Qinsight, it can also start with a training session by one of the team members.

-> Have a look at https://www.quetzal-search.info for more information
4. Karger: Open for Open
4. The Karger Approach.

Open Access – Open Science

The Future is Open. The Future is now.

Karger understands Open Access as one part of the Open Science movement, which we see as essential, exciting developments.

We are moving towards an open access-based publishing landscape in the academic world.

However, not all (geographical) markets are moving and evolving at the same speed, OA is driven by different stakeholders with different requirements. As a publisher we need to try and accommodate these to the best we can.

→ The aim today is to give you a short overview on our approach to Open Access and open the discussion.
4. Karger: Open for Open

How Karger is helping advance the OA transition

- Green OA policy (generous policy – technical support e.g. Deep Green, NIH transfers)
- Improving workflows, reporting capabilities (responding to stakeholder needs)
- Policies to support OA, researcher needs/funder requests, e.g. supporting sharing of preprints
- Flexible transitioning models based on market/institution requirements
- The strategy emphasizes partnership with institutions, societies, researchers. ➔ Understanding your needs!
4. Karger: Open for Open

Open Access: Flipping of Journals

In 2020 we have started actively flipping of journals from subscription model to OA:

- Gastrointestinal Tumors
- Inflammatory Intestinal Diseases
- Kidney Diseases
- Lifestyle Genomics
- Liver Cancer
1. «Partner Publications»:
A journal is published in cooperation with an institution. Ideally fully financed by the partnering institution (no APCs for authors) = Platinum Open Access
→ Model in the Middle East
4. Karger: Open for Open

**Publishing Services & Agreements, main models**

2. **Vouchers for OA Publishing:**
   Upfront payment for publishing Open Access articles in Open Access or hybrid journals, in combination with Access to the Karger collections.

→ mostly in emerging markets: Russia, Latin America, India

3. **Offsetting Deal:**
   Also called Transformative agreements.
   → Part of the existing sales revenue is used for publishing services (APCs)
4. Karger: Open for Open

Karger Offsetting Agreements

• Active Deal since 2016, with the UKB in the Netherlands, currently running in the second term
• For 2020 in discussions with various European Consortia: Sweden, Germany, Czech Elib, JISC (UK), …
• Pilot Projects in the US market
• Different Models based on market and consortia requirements: including Publish-and-Read, Read-and-Publish, Voucher-based, credit deposit based
• Karger guarantees budget security and cost caps (first and second/third year)
4. Karger: Open for Open

Working together towards Open Access and Open Science

Karger’s new strategy sails under the slogan «Connecting and Advancing Health Sciences».

We continue to work on improving our workflows and making transformative agreements.

We are striving for our customers to become more than our customers – striving for them to become our partners.

By understanding your needs and adapting to the new environment, we aim to continue contributing to progress in medical research.

So… tell us what you need!
For any question, documentation, or set-up of a trial, don’t hesitate

We are there to listen to you!

😊

Karger contact:

Séverine Maes
Regional Manager Northern Europe
s.maes@karger.com